<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02032550</url>
  </required_header>
  <id_info>
    <org_study_id>PCC201</org_study_id>
    <nct_id>NCT02032550</nct_id>
  </id_info>
  <brief_title>Treatment Preference and Patient Centered Prostate Cancer Care</brief_title>
  <official_title>Treatment Preference and Patient Centered Prostate Cancer Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corporal Michael J. Crescenz VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a preference based decision aid to assess the&#xD;
      treatment preferences of prostate cancer patients, and to analyze the interaction of&#xD;
      treatment preferences, type of treatment received and their relationship with health related&#xD;
      quality of life, satisfaction with care, decision regret, and psychological health of men&#xD;
      with localized prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to test the comparative effectiveness of a conjoint analysis decision aid&#xD;
      intervention compared to usual care. The investigators will identify preferred attributes of&#xD;
      prostate cancer treatments that will help in designing a conjoint analysis decision aid to&#xD;
      help patients weigh treatment attributes. The investigators will employ values markers to&#xD;
      represent clusters of values for particular aspects of treatments that are valued most by&#xD;
      individual patients. The investigators will test if the concordance between values markers&#xD;
      and treatment received is predictive of objective outcomes and subjective outcomes. The study&#xD;
      hypothesis is that conjoint task may help in treatment choice and prostate cancer patients&#xD;
      whose treatment is more concordant with their values markers will have improved outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 26, 2018</completion_date>
  <primary_completion_date type="Actual">January 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Satisfaction With Care</measure>
    <time_frame>baseline, 3, 6, 12 and 24 months</time_frame>
    <description>The investigators will measure Satisfaction with Care (PSQ-18). : The PSQ-18 scale measures satisfaction with care at baseline 3, 6, 12, and 24 months. Higher score indicates better satisfaction with care. Positive change indicates improvement in satisfaction with care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Generic Health Related Quality of Life (HRQoL)</measure>
    <time_frame>baseline to 24 month</time_frame>
    <description>Generic HRQoL data is obtained from Medical Outcome Study Short Form (SF-36) that assesses 8 health domains. Scores on each domain range from 0 to 100, higher scores indicating better generic HRQoL. Change in SF-36 domain scores between baseline to 24 month will be calculated as score at 24 month-score minus score at baseline. Positive change value indicates improvement in HRQoL from baseline to 24 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
    <description>Anxiety will be measured using Memorial Anxiety Scale for Prostate Cancer (MAX-PC) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Symptoms</measure>
    <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
    <description>The American Urological Association Symptom Index (AUA-SI) will be used to measured urinary symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Choice</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators will obtain data on primary and secondary treatments received, such as active surveillance, radical prostatectomy (RP), robotic-assisted laparoscopic prostatectomy (RALP), external beam radiation therapy (EBRT), brachytherapy (BT) or proton therapy (PT) via self report and verified from medical chart review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
    <description>The Center for Epidemiologic Studies Depression (CES-D) scale will be used to measure depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Decision</measure>
    <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
    <description>The Satisfaction with Decision (SWD) will be used to measure satisfaction with decision at 3, 6, 12 and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Health Related Quality of Life (HRQoL)</measure>
    <time_frame>Baseline to 24 month</time_frame>
    <description>Prostate specific HRQoL data is obtained from Expanded Prostate Cancer Index (EPIC), and measures four broad domains of urinary, bowel, sexual and hormonal symptoms. Scores on each sub-scale range from 0 to 100, with higher scores indicating better prostate cancer HRQoL. Proportion of participants returning to baseline scores will be calculated by comparing scores at baseline and at 24 month. Higher proportion indicates higher number of participants recovering baseline function by 24 month.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Preference for Participation in Treatment Decision</measure>
    <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
    <description>The Control Preferences Scale (CPS) assesses the role that patients want to play and perceive playing in treatment decisions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Decision Conflict</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>The Decision Conflict Scale (DCS) will be used to measure decision conflict.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physician Trust</measure>
    <time_frame>baseline</time_frame>
    <description>The Patient Trust-Wake Forest Physician Trust Scale will be used to measure trust</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">743</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Preference Based Decision Aid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized into this group will have usual care from their doctors without any intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preference Based Decision Aid</intervention_name>
    <description>The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.</description>
    <arm_group_label>Preference Based Decision Aid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed with non-metastatic prostate cancer&#xD;
&#xD;
          2. Has not yet started radiation or surgery&#xD;
&#xD;
          3. Provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distant, metastatic prostate cancer at diagnosis&#xD;
&#xD;
          2. Has already begun treatment for prostate cancer&#xD;
&#xD;
          3. Unable to communicate in English&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravishankar Jayadevappa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia Veteran's Affairs Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <results_first_submitted>March 23, 2018</results_first_submitted>
  <results_first_submitted_qc>July 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2020</results_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Localized prostate cancer</keyword>
  <keyword>Patient preference</keyword>
  <keyword>Treatment choice</keyword>
  <keyword>Decision making</keyword>
  <keyword>Patient centered outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 30, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02032550/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Preference Based Decision Aid</title>
          <description>The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.&#xD;
Preference Based Decision Aid: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Participants randomized into this group will have usual care from their doctors without any intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
                <participants group_id="P2" count="372"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="343"/>
                <participants group_id="P2" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis includes all participants that were randomized to the intervention group or to the usual care group.</population>
      <group_list>
        <group group_id="B1">
          <title>Preference Based Decision Aid</title>
          <description>The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.&#xD;
Preference Based Decision Aid: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Participants randomized into this group will have usual care from their doctors without any intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="371"/>
            <count group_id="B2" value="372"/>
            <count group_id="B3" value="743"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="8.0"/>
                    <measurement group_id="B2" value="63.5" spread="7.6"/>
                    <measurement group_id="B3" value="63.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="371"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="706"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="306"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="601"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="371"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Satisfaction with care</title>
          <description>In the Patient Satisfaction Questionnaire (PSQ-18) survey, 18 items are consolidated into seven subscales to assess satisfaction with medical care and six aspects of care. The subscale score ranges between 1 and 5, with a higher score indicating higher satisfaction. The PSQ-18 has demonstrated good internal consistency (Cronbach's a, .86) and excellent test-retest reliability (r, 0.92).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.96" spread="0.74"/>
                    <measurement group_id="B2" value="3.80" spread="0.81"/>
                    <measurement group_id="B3" value="3.88" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Satisfaction With Care</title>
        <description>The investigators will measure Satisfaction with Care (PSQ-18). : The PSQ-18 scale measures satisfaction with care at baseline 3, 6, 12, and 24 months. Higher score indicates better satisfaction with care. Positive change indicates improvement in satisfaction with care.</description>
        <time_frame>baseline, 3, 6, 12 and 24 months</time_frame>
        <population>All participants from both groups who were analyzed at end of 24 month follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Preference Based Decision Aid</title>
            <description>The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.&#xD;
Preference Based Decision Aid: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants randomized into this group will have usual care from their doctors without any intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Satisfaction With Care</title>
          <description>The investigators will measure Satisfaction with Care (PSQ-18). : The PSQ-18 scale measures satisfaction with care at baseline 3, 6, 12, and 24 months. Higher score indicates better satisfaction with care. Positive change indicates improvement in satisfaction with care.</description>
          <population>All participants from both groups who were analyzed at end of 24 month follow-up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.05"/>
                    <measurement group_id="O2" value="0.07" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.05"/>
                    <measurement group_id="O2" value="0.06" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.05"/>
                    <measurement group_id="O2" value="0.15" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 24 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.06"/>
                    <measurement group_id="O2" value="0.07" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Generic Health Related Quality of Life (HRQoL)</title>
        <description>Generic HRQoL data is obtained from Medical Outcome Study Short Form (SF-36) that assesses 8 health domains. Scores on each domain range from 0 to 100, higher scores indicating better generic HRQoL. Change in SF-36 domain scores between baseline to 24 month will be calculated as score at 24 month-score minus score at baseline. Positive change value indicates improvement in HRQoL from baseline to 24 month.</description>
        <time_frame>baseline to 24 month</time_frame>
        <population>All participants from both groups were analyzed at 24 month. Change in scores on domain of Physical Function is reported below.</population>
        <group_list>
          <group group_id="O1">
            <title>Preference Based Decision Aid</title>
            <description>The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.&#xD;
Preference Based Decision Aid: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants randomized into this group will have usual care from their doctors without any intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Generic Health Related Quality of Life (HRQoL)</title>
          <description>Generic HRQoL data is obtained from Medical Outcome Study Short Form (SF-36) that assesses 8 health domains. Scores on each domain range from 0 to 100, higher scores indicating better generic HRQoL. Change in SF-36 domain scores between baseline to 24 month will be calculated as score at 24 month-score minus score at baseline. Positive change value indicates improvement in HRQoL from baseline to 24 month.</description>
          <population>All participants from both groups were analyzed at 24 month. Change in scores on domain of Physical Function is reported below.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.4"/>
                    <measurement group_id="O2" value="-2.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety</title>
        <description>Anxiety will be measured using Memorial Anxiety Scale for Prostate Cancer (MAX-PC) scale</description>
        <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Symptoms</title>
        <description>The American Urological Association Symptom Index (AUA-SI) will be used to measured urinary symptoms</description>
        <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Choice</title>
        <description>The investigators will obtain data on primary and secondary treatments received, such as active surveillance, radical prostatectomy (RP), robotic-assisted laparoscopic prostatectomy (RALP), external beam radiation therapy (EBRT), brachytherapy (BT) or proton therapy (PT) via self report and verified from medical chart review.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <description>The Center for Epidemiologic Studies Depression (CES-D) scale will be used to measure depression.</description>
        <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Decision</title>
        <description>The Satisfaction with Decision (SWD) will be used to measure satisfaction with decision at 3, 6, 12 and 24 months.</description>
        <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Health Related Quality of Life (HRQoL)</title>
        <description>Prostate specific HRQoL data is obtained from Expanded Prostate Cancer Index (EPIC), and measures four broad domains of urinary, bowel, sexual and hormonal symptoms. Scores on each sub-scale range from 0 to 100, with higher scores indicating better prostate cancer HRQoL. Proportion of participants returning to baseline scores will be calculated by comparing scores at baseline and at 24 month. Higher proportion indicates higher number of participants recovering baseline function by 24 month.</description>
        <time_frame>Baseline to 24 month</time_frame>
        <population>All participants from both groups were analyzed at 24 month. Proportion returning to baseline scores is reported for domain of urinary function below.</population>
        <group_list>
          <group group_id="O1">
            <title>Preference Based Decision Aid</title>
            <description>The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.&#xD;
Preference Based Decision Aid: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Participants randomized into this group will have usual care from their doctors without any intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Health Related Quality of Life (HRQoL)</title>
          <description>Prostate specific HRQoL data is obtained from Expanded Prostate Cancer Index (EPIC), and measures four broad domains of urinary, bowel, sexual and hormonal symptoms. Scores on each sub-scale range from 0 to 100, with higher scores indicating better prostate cancer HRQoL. Proportion of participants returning to baseline scores will be calculated by comparing scores at baseline and at 24 month. Higher proportion indicates higher number of participants recovering baseline function by 24 month.</description>
          <population>All participants from both groups were analyzed at 24 month. Proportion returning to baseline scores is reported for domain of urinary function below.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Preference for Participation in Treatment Decision</title>
        <description>The Control Preferences Scale (CPS) assesses the role that patients want to play and perceive playing in treatment decisions.</description>
        <time_frame>baseline, 3, 6, 12, and 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Decision Conflict</title>
        <description>The Decision Conflict Scale (DCS) will be used to measure decision conflict.</description>
        <time_frame>12 and 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Physician Trust</title>
        <description>The Patient Trust-Wake Forest Physician Trust Scale will be used to measure trust</description>
        <time_frame>baseline</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Preference Based Decision Aid</title>
          <description>The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.&#xD;
Preference Based Decision Aid: The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Participants randomized into this group will have usual care from their doctors without any intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ravishankar Jayadevappa</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-898-3798</phone>
      <email>jravi@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

